Oncternal Therapeutics Inc banner

Oncternal Therapeutics Inc
F:GTU2

Watchlist Manager
Oncternal Therapeutics Inc Logo
Oncternal Therapeutics Inc
F:GTU2
Watchlist
Price: 5.32 EUR Market Closed
Market Cap: €948.1k

Wall St Price Targets

GTU2 Price Targets Summary
Oncternal Therapeutics Inc

There are no price targets for GTU2.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Oncternal Therapeutics Inc Competitors:
Price Targets
ANY
ANY Biztonsagi Nyomda Nyrt
16% Upside

Revenue
Forecast

-28% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss
-28% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been -28%. The projected CAGR for the next 3 years is 9%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Oncternal Therapeutics Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Oncternal Therapeutics Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Oncternal Therapeutics Inc
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GTU2's stock price target?
Not Available

GTU2 does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Oncternal Therapeutics Inc?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Revenue has been -28%. The projected CAGR for the next 3 years is 9%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett